ALK and non-small cell lung carcinoma: This work also revealed high frequencies of ALK mutations in intermediate-risk NBs of young stage 4 patients, suggesting the potential therapeutic benefits of ALK inhibitors in this subgroup.50 Point mutations and plasticity of NB are key factors in determining the response to ALK inhibition when compared to the adult inflammatory myofibroblastic tumors or non-small cell lung carcinomas, which are more sensitive and present instead ALK fusion proteins.